PACB Stock Forecast: Pacific Biosciences of California, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Pacific Biosciences of California, Inc. hold a median 12-month price target of $3 — +84.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 68 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Pacific Biosciences of California, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (96): Sales and profits are climbing, and climbing faster than before.
Issuance (32): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PACB stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PACB, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +84.0% from it.
Of the 20 most recent actions, 3 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | UBS | Maintains | Neutral | $3.05 → $2.70 |
| 5 Nov 2026 | Barclays | Maintains | Underweight | $1.25 → $2.00 |
| 5 Nov 2026 | Piper Sandler | Reiterates | Neutral | $2.00 → $3.00 |
| 9 Sept 2026 | UBS | Assumes | Neutral | $1.50 → $1.35 |
| 11 May 2026 | Barclays | Maintains | Underweight | $1.00 → $1.50 |
| 14 Apr 2026 | Barclays | Maintains | Underweight | — |
| 6 Mar 2026 | Barclays | Downgrade | Underweight | — |
| 15 Dec 2025 | Barclays | Maintains | Equal-Weight | — |
| 11 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
| 10 Nov 2025 | Stephens & Co. | Maintains | Overweight | — |
| 11 Aug 2025 | Piper Sandler | Maintains | Neutral | — |
| 25 June 2025 | Barclays | Maintains | Equal-Weight | — |
| 15 May 2025 | Piper Sandler | Maintains | Neutral | — |
| 15 May 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 10 Apr 2025 | Canaccord Genuity | Maintains | Buy | — |
| 25 Mar 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 20 Feb 2025 | Piper Sandler | Reiterates | Neutral | — |
| 18 Feb 2025 | Goldman Sachs | Maintains | Neutral | — |
| 18 Feb 2025 | Stephens & Co. | Reiterates | Overweight | — |
| 14 Feb 2025 | Stephens & Co. | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PACB.
This page is one stock. Monday covers all of them.
PACB appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PACB vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Pacific Biosciences of California, Inc. returned −13.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PACB analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 3.3×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 33% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 32.4%
- Operating margin
- —
- Net margin
- −81.3%
Higher than 37% of US stocks
Higher than 7% of US stocks
- Return on equity
- —
- Return on assets
- −44.1%
- Dividend yield
- —
Higher than 9% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pacific Biosciences of California, Inc. has a market value of $549.5M and an enterprise value of $1.1B.
Revenue in the twelve months to 30 June 2026: $159.3M. The latest quarter shrank 1.9% year on year.
Net income over the same four quarters: −$131.4M, a −82.5% net margin.
Diluted earnings per share, trailing twelve months: −$0.43.
Free cash flow in the twelve months to 30 June 2026: −$130.5M.
Pacific Biosciences of California, Inc. employs 485 people — $328K of revenue per employee.
Data provided by Twelve Data
PACB and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PACB’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Pacific Biosciences of California, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PACB
What is the PACB stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Pacific Biosciences of California, Inc. have a median 12-month price target of $3, with estimates ranging from $2 to $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PACB stock a buy right now?
Of the 8 analysts covering Pacific Biosciences of California, Inc., 4 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Pacific Biosciences of California, Inc. 68 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PACB?
As at 21 Nov 2026, Pacific Biosciences of California, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).
Will PACB stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +84.0% from the last close, and Ticker Nerd's factor model ranks Pacific Biosciences of California, Inc. 68 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PACB stock forecast for 2030?
No analyst covering Pacific Biosciences of California, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PACB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $3 over the next 12 months.
How has PACB stock performed over the past year?
Pacific Biosciences of California, Inc. returned -13.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Pacific Biosciences of California, Inc. do?
Pacific Biosciences of California, Inc. is a life sciences technology company that develops, manufactures, and markets advanced genetic sequencing solutions. Its core offering is HiFi long-read sequencing, supported by Single Molecule, Real-Time technology designed to produce highly accurate, detailed views of DNA.
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. is a life sciences technology company that develops, manufactures, and markets advanced genetic sequencing solutions. Its core offering is HiFi long-read sequencing, supported by Single Molecule, Real-Time technology designed to produce highly accurate, detailed views of DNA. The company provides sequencing instruments, consumables, reagent kits, sample-preparation products, binding kits, and related laboratory solutions for genomic analysis workflows. Its technologies serve research institutions, clinical laboratories, pharmaceutical and biotechnology companies, agricultural organizations, and other customers working with complex genetic material. Applications include human genome and germline analysis, oncology research, infectious disease and microbiology studies, plant and animal sciences, population genomics, and other fields requiring comprehensive DNA characterization. Pacific Biosciences of California, Inc. occupies a specialized role in the genomics market by supporting long-read analysis, which can help researchers investigate genetic regions and structural variations that may be difficult to resolve with shorter sequencing methods.
CEO Mr. Mark Van Oene Ph.D. · 485 employees · United States · https://www.pacb.com